IL‐6 increases glucocorticoid levels in the serum, which may impair the infiltration and proliferation of CD8+ T cells within the tumor and weaken the therapeutic effects of PD‐1/PD‐L1 inhibitors.9, 36. This evidence concerns the gene CD274 and neoplasm.